Taiwan
· Delayed Price · Currency is TWD Diamond Biofund Statistics
Total Valuation
Diamond Biofund has a market cap or net worth of TWD 19.68 billion. The enterprise value is 14.74 billion.
| Market Cap | 19.68B |
| Enterprise Value | 14.74B |
Important Dates
The last earnings date was Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Diamond Biofund has 851.80 million shares outstanding. The number of shares has increased by 5.86% in one year.
| Current Share Class | 851.80M |
| Shares Outstanding | 851.80M |
| Shares Change (YoY) | +5.86% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 25.24% |
| Owned by Institutions (%) | 5.17% |
| Float | 179.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -9.83 |
| PB Ratio | 2.01 |
| P/TBV Ratio | 2.01 |
| P/FCF Ratio | 6.33 |
| P/OCF Ratio | 6.32 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.46 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 4.74 |
Financial Position
The company has a current ratio of 27.71, with a Debt / Equity ratio of 0.01.
| Current Ratio | 27.71 |
| Quick Ratio | 27.70 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.04 |
| Interest Coverage | -595.66 |
Financial Efficiency
Return on equity (ROE) is -20.86% and return on invested capital (ROIC) is -12.26%.
| Return on Equity (ROE) | -20.86% |
| Return on Assets (ROA) | -12.15% |
| Return on Invested Capital (ROIC) | -12.26% |
| Return on Capital Employed (ROCE) | -21.92% |
| Revenue Per Employee | -60.65M |
| Profits Per Employee | -69.15M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.52% in the last 52 weeks. The beta is 1.51, so Diamond Biofund's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -41.52% |
| 50-Day Moving Average | 25.77 |
| 200-Day Moving Average | 33.87 |
| Relative Strength Index (RSI) | 46.74 |
| Average Volume (20 Days) | 442,038 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diamond Biofund had revenue of TWD -2.00 billion and -2.28 billion in losses. Loss per share was -2.68.
| Revenue | -2.00B |
| Gross Profit | -2.00B |
| Operating Income | -2.17B |
| Pretax Income | -2.16B |
| Net Income | -2.28B |
| EBITDA | -2.16B |
| EBIT | -2.17B |
| Loss Per Share | -2.68 |
Balance Sheet
The company has 5.05 billion in cash and 111.92 million in debt, giving a net cash position of 4.94 billion or 5.80 per share.
| Cash & Cash Equivalents | 5.05B |
| Total Debt | 111.92M |
| Net Cash | 4.94B |
| Net Cash Per Share | 5.80 |
| Equity (Book Value) | 9.81B |
| Book Value Per Share | 11.51 |
| Working Capital | 4.88B |
Cash Flow
In the last 12 months, operating cash flow was 3.11 billion and capital expenditures -2.59 million, giving a free cash flow of 3.11 billion.
| Operating Cash Flow | 3.11B |
| Capital Expenditures | -2.59M |
| Free Cash Flow | 3.11B |
| FCF Per Share | 3.65 |
Margins
| Gross Margin | n/a |
| Operating Margin | 108.42% |
| Pretax Margin | 107.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Diamond Biofund does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.86% |
| Shareholder Yield | -5.86% |
| Earnings Yield | -11.60% |
| FCF Yield | 15.80% |
Stock Splits
The last stock split was on August 7, 2023. It was a forward split with a ratio of 1.18.
| Last Split Date | Aug 7, 2023 |
| Split Type | Forward |
| Split Ratio | 1.18 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |